Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
J Clin Virol ; 66: 33-7, 2015 May.
Article in English | MEDLINE | ID: mdl-25866333

ABSTRACT

BACKGROUND: Hepatitis delta virus (HDV) testing is recommended for all patients with hepatitis B virus (HBV) infection. HDV infection is associated with severe liver disease and interferon is the only available treatment. OBJECTIVES: To determine the rate of anti-HDV antibody testing in HBV patients; and to describe the epidemiology, clinical characteristics and management of HDV-infected patients at four hospitals in London. STUDY DESIGN: The anti-HDV testing rate was estimated by reviewing clinical and laboratory data. Cross-sectional data collection identified HDV-infected patients who had attended the study centres between 2005 and 2012. RESULTS: At a centre with clinic-led anti-HDV testing, 40% (67/168) of HBV patients were tested. Recently diagnosed HBV patients were more likely to be screened than those under long-term follow-up (62% vs 36%, P=0.01). At a centre with reflex laboratory testing, 99.4% (3543/3563) of first hepatitis B surface antigen positive samples were tested for anti-HDV. Across the four study centres there were 55 HDV-infected patients, of whom 50 (91%) had immigrated to the UK and 27 (49%) had evidence of cirrhosis. 31 patients received interferon therapy for HDV with an end of treatment virological response observed in 10 (32%). CONCLUSIONS: The anti-HDV testing rate was low in a centre with clinic-led testing, but could not be evaluated in all centres. The HDV-infected patients were of diverse ethnicity, with extensive histological evidence of liver disease and poor therapeutic responses. Future recommendations include reflex laboratory testing algorithms and a prospective cohort study to optimise the investigation and management of these patients.


Subject(s)
Diagnostic Tests, Routine/statistics & numerical data , Hepatitis Antibodies/blood , Hepatitis D/diagnosis , Hepatitis D/therapy , Hepatitis Delta Virus/immunology , Mass Screening/statistics & numerical data , Adult , Cross-Sectional Studies , Female , Health Services Research , Hepatitis B, Chronic/complications , Hepatitis D/epidemiology , Humans , Immunologic Factors/therapeutic use , Interferons/therapeutic use , London/epidemiology , Male , Middle Aged
2.
BMC Gastroenterol ; 14: 60, 2014 Apr 02.
Article in English | MEDLINE | ID: mdl-24694003

ABSTRACT

BACKGROUND: Ajmaline is a pharmaceutical agent now administered globally for a variety of indications, particularly investigation of suspected Brugada syndrome. There have been previous reports suggesting that repetitive use of this agent may cause severe liver injury, but little evidence exists demonstrating the same effect after only a single administration. CASE PRESENTATION: A 33-year-old man of Libyan origin with no significant past medical history underwent an ajmaline provocation test for investigation of suspected Brugada syndrome. Three weeks later, he presented with painless cholestatic jaundice which peaked in severity at eleven weeks after the test. Blood tests confirmed no evidence of autoimmune or viral liver disease, whilst imaging confirmed the absence of biliary tract obstruction. A liver biopsy demonstrated centrilobular cholestasis and focal rosetting of hepatocytes, consistent with a cholestatic drug reaction. Over the course of the next few months, he began to improve clinically and biochemically, with complete resolution by one year post-exposure. CONCLUSION: Whilst ajmaline-related hepatotoxicity was well-recognised in the era in which the drug was administered as a regular medication, clinicians should be aware that ajmaline may induce severe cholestatic jaundice even after a single dose administration.


Subject(s)
Ajmaline/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Jaundice, Obstructive/chemically induced , Voltage-Gated Sodium Channel Blockers/adverse effects , Adult , Brugada Syndrome/diagnosis , Chemical and Drug Induced Liver Injury/pathology , Humans , Jaundice, Obstructive/pathology , Male , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...